NCT00174447View on ClinicalTrials.gov

Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

Ziprasidone

Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid

Trial Locations (14)

31000

Pfizer Investigational Site, Toulouse

31200

Pfizer Investigational Site, Toulouse

35000

Pfizer Investigational Site, Rennes

38521

Pfizer Investigational Site, Saint-Égrève

39108

Pfizer Investigational Site, DOLE Saint YLIE

44700

Pfizer Investigational Site, Orvault

62800

Pfizer Investigational Site, Liévin

67100

Pfizer Investigational Site, Strasbourg

69373

Pfizer Investigational Site, Lyon

70160

Pfizer Investigational Site, Saint-Rémy

78000

Pfizer Investigational Site, Versailles

83056

Pfizer Investigational Site, Toulon

84000

Pfizer Investigational Site, Avignon

84143

Pfizer Investigational Site, Montfavet

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00174447 - Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031 | Biotech Hunter | Biotech Hunter